TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
RNA

Atrium Therapeutics, Inc.

Healthcare · Biotechnology

8.10$ -1.8% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Balance Sheet

Atrium Therapeutics, Inc. (RNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 281 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RNA
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
573 629 951 1,347 1,641 1,564 1,459 1,369 278 278 292 281
555 611 934 1,329 1,622 1,542 1,435 1,251 271 273 286 275
86 185 471 576 370 220 254 244 270 270 268 73
543 595 916 1,299 1,589 1,501 1,380 1,183 270 270 268 264
1.0 8.6 9.0 16 19 28 37 8.5 15 12 15 –
-1.0 – – -16 – – – – – – – –
56 128 121 126 137 139 130 176 65 71 58 66
49 81 75 84 91 98 85 135 32 42 22 32
3.6 3.6 3.7 3.8 3.8 3.8 3.9 3.9 4.0 3.7 2.7 1.7
5.6 8.8 2.3 8.9 7.7 8.5 6.6 3.9 0.5 4.4 0.8 3.5
517 501 831 1,221 1,503 1,425 1,329 1,193 213 207 234 215
-510 -571 -640 -710 -791 -893 -1,009 -1,166 -1,341 -1,578 12 -8.1
74 76 87 107 123 128 129 130 138 17 17 17

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?